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1

Introduction

Clinical trial data are often monitored repeatedly during the conduct of a study in order to address the efficiency and ethical issues inherent in human experimentation. Decisions regarding the
continuation of the study are typically guided by a group sequential stopping rule which specifies
the conditions under which the clinical trial results might be judged sufficiently convincing to allow
early stopping. In a companion paper to this manuscript [1], we consider the evaluation of a clinical trial design with respect to frequentist operating characteristics such as type I error, statistical
power, sample size requirements, estimates of treatment effect which correspond to early termination, and precision of confidence intervals. Increasingly, however, there has been much interest in
the design and analysis of clinical trials under a Bayesian paradigm. We thus turn our attention to
the evaluation of Bayesian operating characteristics for a clinical trial design.
In considering the Bayesian approach, we again take the stance that the derivation of the
stopping rule is relatively unimportant. That is, in the companion paper, we demonstrate the 1:1
correspondence between stopping rules defined for frequentist statistics (on a variety of scales) and
Bayesian statistics for a specified prior. Hence, our focus in this paper will be on the computation
and presentation of Bayesian operating characteristics for a specified stopping rule. The primary
issues to be addressed will be the selection of suitable probability models and families of prior
distributions which will allow a standard, concise communication of design precision and statistical
inference. In particular, our interest is in providing Bayesian inference in the context of a probability
model similar to that which would be assumed in the most common frequentist analyses. For the
purposes of brevity, we will consider only a single stopping rule in our illustration, although in
practice we would compare the Bayesian operating characteristics among several candidate stopping
rules in much the same way that frequentist operating characteristics were compared across stopping
rules in the companion paper.
In illustrating our approach to evaluating Bayesian operating characteristics, we will appeal to
the same example as used in the companion paper. In section 2, we provide a brief review of the
scientific setting and basic statistical design of the clinical trial. Then in section 3 we present the
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general Bayesian paradigm and the nonparametric, “coarsened Bayesian” approach we adopt here,
along with a discussion of the the choice of prior distributions. In section 4 present a general scheme
for presenting the Bayesian operating characteristics in a relatively concise manner. We conclude
in section 5 with some general comments regarding the practical use of the proposed approach to
Bayesian evaluation of clinical trial designs.

2

Example Used for Illustration

We illustrate our approach in the context of a randomized, double-blind, placebo-controlled clinical
trial of an antibody to endotoxin in the treatment of gram-negative sepsis. Details of the scientific
setting and the clinical trial design are provided in the companion paper [1].

2.1

Notation and Sample Size

Briefly, a maximum of 1,700 patients with proven gram-negative sepsis were to be randomly assigned
in a 1:1 ratio to receive a single dose of antibody to endotoxin or placebo. The primary endpoint
for the trial was to be the 28 day mortality rate, which was anticipated to be 30% in the placebo
treated patients and was hoped to be 23% in the patients receiving antibody. Notationally, we let
Xki be an indicator that the i-th patient on the k-th treatment arm (k=0 for placebo, k= 1 for
antibody) died in the first 28 days following randomization. Thus Xki = 1 if the i-th patient on
treatment arm k dies in the first 28 days following randomization, and Xki = 0 otherwise. We are
interested in the probability model in which the random variables Xki are independently distributed
according to a Bernoulli distribution B(1, pk ), where pk is the unknown 28 day mortality rate on
the k-th treatment arm. We use the difference in 28 day mortality rates θ = p1 − p0 as the measure
of treatment effect.
Supposing the accrual of N subjects on each treatment arm, a frequentist analysis of clinical trial
P
results was to be based on asymptotic arguments which suggest that p̂k = N
i=1 Xki /N is approximately normally distributed with mean pk and variance pk (1 − pk )/N . In a study which accrued N
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subjects per arm we therefore have an approximate distribution for the estimated treatment effect
θ̂ = p̂1 − p̂0 of
θ̂ ∼
˙ N



p1 (1 − p1 ) + p0 (1 − p0 )
θ,
N



.

(1)

As is customary in the setting of tests of binomial proportions, at the time of data analysis the
actual frequentist test statistic will estimate a common mortality rate p̂ under the null hypothesis
of no treatment effect. Thus, if at the time of data analysis n0 and n1 patients had been accrued to
the placebo and treatment arms, respectively, and the respective observed 28 day mortality rates
were p̂0 and p̂1 , the test statistic used to test the null hypothesis would be

Z=r

p̂1 − p̂0

p̂(1 − p̂) n11 +

1
n0

,

where the common mortality rate under the null hypothesis is estimated by

p̂ =

n1 p̂1 + n0 p̂0
.
n0 + n1

In a fixed sample study, the 1,700 subjects (850 per arm) provide statistical power of 0.9066 to
detect the design alternative of θ = −0.07 when the control group’s 28 day mortality rate if 30%.
If the estimated variability of θ̂ at the conclusion of such a trial were to agree exactly with the
variance used in the sample size calculation, the null hypothesis would be rejected in a frequentist
hypothesis test if the absolute difference in 28 day mortality rates showed that the mortality on
the antibody arm was at least .0418 lower than that on the placebo arm (i.e., we would reject H0
if and only if θ̂ < − 0.0418).

2.2

Definition of Stopping Rules

A stopping rule is defined for a schedule of analyses occurring at sample sizes N1 , N2 , . . . , NJ .
For j = 1, . . . , J, we calculate treatment effect estimate θ̂j based on the first Nj observations. The
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outcome space for θ̂j is then partitioned into stopping set Sj and continuation set Cj . Starting
with j = 1, the clinical trial proceeds by computing test statistic θ̂j , and if θ̂j ∈ Sj , the trial is
stopped. Otherwise, θ̂j is in the continuation set Cj , and the trial gathers observations until the
available sample size is Nj+1 . By choosing CJ = ∅, the empty set, the trial must stop at or before
the J-th analysis.
For the purposes of our illustration, we consider the stopping rule actually used in the sepsis
clinical trial. Using the nomenclature from the companion paper [1], the stopping rule Futility.8 is a level 0.025 one-sided stopping rules from the unified family [2] having O’Brien-Fleming
lower (efficacy) boundary relationships and upper (futility) boundary relationships corresponding
to boundary shape parameters P = 0.8. In this parameterization of the boundary shape function,
parameter P is a measure of conservatism at the earliest analyses. P = 0.5 corresponds to Pocock
boundary shape functions, and P = 1.0 corresponds to O’Brien-Fleming boundary relationships.
The choice P = 0.8 is thus intermediate between those two, and tends to be fairly similar to a
triangular test stopping boundary. Table 1 presents the stopping boundaries on the scale of the
crude estimate of treatment effect θ̂j for four equally spaced analyses.

3

Bayesian Paradigm

~ for the treatment effect parameter
In the Bayesian paradigm, we consider a joint distribution p(θ, X)
~ The marginal distribution pθ (θ) is commonly termed the “prior”
θ and the clinical trial data X.
distribution for the treatment effect parameter, because it represents the information about θ prior
~ From a clinical trial, we observe data
to (in the absence of) any knowledge of the value of X.
~ = ~x and base inference on the conditional distribution p ~ (θ|X
~ = ~x), which is commonly
X
θ|X
termed the “posterior” distribution. As with frequentist inference, we are interested in point and
interval estimates of a treatment effect, a measure of strength of evidence for or against particular
hypotheses, and perhaps a binary decision for or against some hypothesis. Commonly used Bayesian
inferential quantities include:
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1. Point estimates of treatment effect which are summary measures of the posterior distri~ = ~x)), the posterior median (θ0.5 such that
bution such as the posterior mean (E(θ|X
~ = ~x) ≥ 0.5 and P r(θ ≥ θ0.5 |X
~ = ~x) ≥ 0.5), or the posterior mode (θm
P r(θ < θ0.5 |X
~ = ~x) ≥ p ~ (θ|X
~ = ~x) for all θ).
such that pθ|X~ (θm |X
θ|X
2. Interval estimates of treatment effect which are computed by finding two values (θL , θU ) such
~ = ~x) = 100(1 − α)%. Various criteria can be used to define such
that P r(θL < θ < θU |X
“credible intervals”:
(a) the central 100(1 − α)% of the posterior distribution of θ is defined by finding some ∆
such that θL = θ̂ − ∆ and θU = θ̂ + ∆ provides the desired coverage probability, where
θ̂ is one of the Bayesian point estimates of θ.
(b) the interquantile interval is defined by defining θL = θα/2 and θU = θ1−α/2 , where θp is
~ = ~x) = p.
the p-th quantile of the posterior distribution, i.e., P r(θ < θp |X
(c) the highest posterior density (HPD) interval is defined by finding some threshold cα
~ = ~x) > cα } and θU = max{θ : p ~ (θ|X
~ =
such that the choices θL = min{θ : pθ|X~ (θ|X
θ|X
~x) > cα } provide the desired coverage probability. (Note that in the case of a multimodal
posterior density, this definition of a HPD interval may include some values of θ for which
the posterior density does not exceed the given threshold. Hence, one could ostensibly
define an HPD region that was smaller in this setting.)
3. Posterior probabilities of specific hypotheses, which might be used by Bayesians to make a
decision for or against a particular hypothesis. For instance, in the sepsis trial example, we
might be interested in computing the posterior probability of the null hypothesis P r(θ ≥
~ = ~x).
~ = ~x) or the posterior probability of the design alternative P r(θ < − 0.07|X
0|X
In specifying a Bayesian probability model, we most often specify the prior distribution pθ (θ)
~
~
and the likelihood function pX|θ
~ (X|θ), rather than specifying the joint distribution p(θ, X) directly.
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~ = ~x, the posterior distribution is then computed using Bayes rule as
Upon observation of X

~ = ~x) = R
pθ|X~ (θ|X

~
pX|θ
~ (X|θ) pθ (θ)
~
pX|θ
~ (X|θ) pθ (θ) dθ

.

We note that the Bayesian inference presented above is unaffected by the choice of stopping
rule, so long as there is no need to consider the joint distribution of estimates across the multiple
analyses of the accruing data. That is, so long as one is content to regard inference at each analysis
marginally, then the stopping rule used to collect the data is immaterial. However, the expected
cost of a clinical trial does depend very much on the stopping rule used, even when Bayesian
inference is used as the basis for a decision.

3.1

Frequentist versus Bayesian Criteria (and the Role of the Likelihood Principle)

As noted above, much of statistical inference is concerned with quantification of the strength of
statistical evidence in support of or against particular hypotheses and with quantification of the
precision with which we can estimate population parameters. There are two major categories of
such inferential methods: Bayesian and frequentist. Frequentist measures of statistical evidence
and precision such as the P value and confidence intervals are currently the most commonly used
approaches upon which statistical decisions are based, and frequentist optimality criteria for estimators such as bias and mean squared error are perhaps most commonly used for selecting the
estimators of treatment effect. However, frequentist inference by no means enjoys universal acceptance [3, 4]. Because frequentist inference merely provides information about the probability of
obtaining the observed data under specific hypotheses, it is not truly addressing the question of
greatest interest: After observing the data, what is the probability that a treatment is truly beneficial? Bayesian inference answers this latter question by assuming a prior probability distribution
for the treatment effect, and then using the data to update that distribution. Many adherents of
Bayesian inference note that it, unlike frequentist inference, adheres to the Likelihood Principle [5].
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The Likelihood Principle states that all information in the data relevant to discriminating between
hypotheses is captured by the ratio of the likelihoods under those hypotheses, and that inference
that is not based on that ratio is not as relevant.
Our position is that there is no true conflict between frequentist and Bayesian inference. Instead, they merely answer different questions. If we consider that there exists a joint distribution of
the parameter θ and the estimate θ̂ of that parameter, then frequentist inference and Bayesian inference can be viewed as considering different conditional distributions derived from that same joint
~ | θ), and Bayesian indistribution: Frequentist inference considers the conditional distribution p(X
~ It is this view that led us to focus primarily
ference considers the conditional distribution p(θ | X).
on the evaluation of stopping rules under frequentist or Bayesian frameworks without regard for the
original derivation of the stopping rule. We regard that it is the role of statistics to help quantify the
strength of evidence used to convince the scientific community of conclusions reached from studies.
As we believe that otherwise reasonable people might demand evidence demonstrating results that
would not typically be obtained under any other hypothesis, our job as statisticians is to try to
answer whether such results have been obtained. These frequentist criteria were addressed in the
companion paper on the frequentist evaluation of stopping rules. We similarly believe that when
people demand evidence that overpowers their prior beliefs in a Bayesian framework, we should also
address those questions. It is this second situation that leads to the focus on Bayesian evaluation
of clinical trial designs in this paper. In adopting this position of accepting both frequentist and
Bayesian inferential measures, we are clearly taking the stance that the Likelihood Principle is not
the only guiding principle of all statistics.
As sequelae of this philosophy of using both frequentist and Bayesian inference to address
different standards of proof within the same setting, it would seem most appropriate to use the
same probability model in each approach. This philosophy also argues that it is never sufficient to
use any single prior distribution for the population parameters when providing Bayesian inference.
We address these issues in greater detail in the following sections.
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3.1.1

Coarsened Bayesian Approach

As noted above, Bayesian inference is based on the conditional distribution of the treatment effect
~ = ~x. Frequentist inference, on the other hand, considers the conditional distribution
parameter θ|X
~
of the data X|θ.
These two approaches to statistical inference are complementary when the same
~ is used for all inference. There is, however, a tendency for frequentists to
probability model p(θ, X)
interpret their inference in a distribution-free manner, while the overwhelming majority of Bayesian
analyses are fully parametric.
The use of parametric analyses (and, indeed, most commonly used semiparametric analyses)
seems inappropriate in the scientific setting of most clinical trials. Most often, the scientific question
to be addressed when investigating a new treatment is whether the treatment results in a tendency
toward higher or lower values for some clinical outcome (but not both). Because of this primary
focus on the central tendency (or location) of some probability distribution, we might choose
measures of treatment effect based on the mean, median, proportion or odds above some clinically
relevant threshold, or the probability that a randomly chosen treated subject would have an outcome
larger than a randomly chosen subject receiving the control treatment (the de facto treatment effect
parameter tested with a Wilcoxon rank sum test). A parametric model in such a setting corresponds
to making assumptions more detailed than the question we are trying to address. For instance,
in the case of inference about the mean outcome, use of a parametric model is tantamount to
admitting that we do not know how the treatment affects the first moment of the distribution of
outcomes, but imagining that we do know how it affects the variance, skewness, kurtosis, and all
higher moments of the probability distribution. Not only does such an assumption seem illogical
based on the current state of knowledge at the start of a clinical trial, but it also seems unlikely that
the effect of a treatment on a population would truly be such that an assumption of this type might
hold. Instead, it is quite likely that unidentified subgroups would be either less or more susceptible
to a treatment. In that setting, a treatment that has some effect on the primary outcome would
tend to have a mixture distribution.
The foundational problem with parametric analyses is also present in those semiparametric
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probability models which assume that a finite dimensional parameter of interest and an infinite dimensional nuisance parameter related to a single population’s distribution provides full information
about the distribution of outcomes in every population. For instance, when comparing means or
medians, some data analysts consider a semiparametric location-shift model in which the control
group has some unknown distribution of outcomes (i.e., P r(X0i < x) = F0 (x) arbitrary), but that
the distribution of outcomes in the treatment group is known to have the shape shifted higher or
lower (i.e., P r(X1i < x) = F0 (x − θ)). Similarly, the proportional hazards model commonly used
in survival analysis allows an arbitrary distribution for the control population, with a relationship
between the control and treatment groups that would have P r(X1i ≥ x) = [P r(X0i ≥ x)]θ . In such
models, the semiparametric distributional assumption can be quite strong, and departures from
the assumption can adversely affect the statistical inference.
Clearly, when a treatment has some effect on the outcome, failure to have the correct parametric
or semiparametric model will mean that the probability statements associated with statistical
inference (e.g., P values, coverage probabilities, posterior means, unbiasedness) will not hold. In
some cases, however, frequentist testing can proceed, because it is based only on knowing the
distribution of the outcome under the null hypothesis. If the null hypothesis to be tested is that
the treatment has no effect on outcome whatsoever, then the null distribution of the estimated
treatment effect can be approximated by pooling all of the data (as is done with the asymptotic
test of two binomial proportions and the Wilcoxon rank sum test), by using only the control group’s
data (which, though not commonly done, could in some cases result in more powerful tests than
the other approaches described here), or by assuming some semiparametric model which reduces to
equivalence of distributions under the null (as is commonly done in the t test for equal variances and
proportional hazards models). In the latter instance, pooled estimates of the nuisance null variance
(in the case of the t test presuming equal variances) or the baseline survivor distribution (in the
case of proportional hazards model) can be used, because under the null hypothesis they would be
estimated correctly. The fact that any of these standard error estimates might be incorrect under
alternative distributions is immaterial, because by hypothesis that can only happen when the null
hypothesis is false. A problem does arise, however, when it comes to scientific interpretation of a
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significant test. For instance, it is easily shown that the t test presuming equal variances and the
Wilcoxon rank sum test will reject the null hypothesis with probability greater than the nominal
type I error in some cases where the treatment affects the variance of the outcome measurements
without affecting the mean, median, or probability that a randomly chosen treated individual has
a measurement larger than a randomly chosen individual in the control group. Because, as noted
above, most scientific questions are more closely related to central tendencies of the distribution of
outcome, this would suggest that the use of such semiparametric models may be misleading even
in the frequentist testing.
Fortunately, however, there are robust (distribution-free) probability models that do allow inference about the most commonly used measures of treatment effect. Koprowicz, et al. [6] note
that so long as asymptotically normally distributed nonparametric estimates of treatment effect
are used along with correct modeling of how the standard errors of those estimates vary under all
alternatives, robust inference is possible. In fact, it is common for frequentist analyses to be based
on nonparametric estimates of treatment effect parameters. Modification of the standard error
estimates (e.g., using the t test for unequal variance rather than the t test for equal variance) then
provides robust inference about the treatment effect in large samples. Such an approach can also be
used for robust Bayesian inference as explored by Pratt, et al. [7], Boos and Monahan [8], Monahan
and Boos [9], and Koprowicz, et al. [6]. In the clinical trial setting, using such an approach allows
frequentist and Bayesian inference to be based on the same probability model– a condition not
easily duplicated when nonparametric Bayesian inference is based on Dirichlet process priors.
We relax some of the more restrictive assumptions of a parametric or semiparametric model and
~ = (X1 , . . . , XN )) consistent for
adopt a robust approach here. A nonparametric estimator θ̂N = t(X
the treatment effect parameter θ is viewed as a coarsening of the data. In a wide variety of settings,
the nonparametric estimator can be shown to be approximately normally distributed with large
sample sizes. Hence, we consider the Bayesian paradigm based on a joint distribution p(θ, θ̂) with
marginal (prior) distribution pθ (θ) for the treatment effect parameter and approximate likelihood
based on an asymptotic distribution θ̂N ∼N
˙ (θ, V (θ)/N ). Hence, the posterior distribution for θ|θ̂N
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is computed according to

p̂θ|θ̂N (θ|θ̂N ) =

q

Rq

N
V (θ) φ

N
V (θ) φ





√(θ̂N −θ)

V (θ)/N

√(θ̂N −θ)
V (θ)/N





pθ (θ)
.
pθ (θ) dθ

Such a coarsening of the data has little effect on the efficiency of Bayesian inference when the
nonparametric estimator is in fact a sufficient statistic for the data. In that case, the only loss of
efficiency is from using the approximate normal distribution of the sufficient statistic rather than
the exact distribution [6].

3.1.2

Choice of Prior Distributions

Bayesian inference depends heavily on the choice of prior distribution pθ (θ) for the treatment
effect parameter. For that reason, Bayesian inferential procedures have sometimes been criticized
because it is not clear how the prior distribution should be selected for any particular problem.
When relevant prior data are available, it would seem most sensible to use that prior data to
derive a prior distribution. Most often, however, the exact relevance of data from pilot studies is
unclear due to changing inclusion/exclusion criteria, changing definitions of the study treatment,
and changing standards of ancillary care. Hence, the prior distribution is probably best regarded
as a subjective probability measuring an individual’s prior belief about the treatment effect.
Much has been written in the statistical literature about methods of eliciting priors from a
consensus of experts, as well as the need to consider a range of priors which cover both “pessimistic”
and “optimistic” priors [4, 10]. While examining inference specific to a single “expert” prior is
indeed often of interest, we regard the sensitivity analysis approach as the more important one. We
believe that many Bayesian data analysts’ failure to do so in the past is, at least in part, responsible
for the lack of greater penetrance of Bayesian methods into the applied clinical trials literature.
That is, the purpose of scientific experimentation is to present to the scientific community (for
early phase trials) and larger clinical community (for phase III studies leading to the adoption
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of new treatments) credible evidence for or against specific hypotheses. As a general rule, the
investigators collaborating on a particular clinical trial are likely to be more optimistic about that
new treatment’s benefits than the typical member of the scientific community. For instance, Carlin
and Louis [11] describe a setting in which the likelihood function suggested a harmful treatment, but
several clinicians had put no prior mass on the possibility of a negative treatment effect. A Bayesian
analysis incorporating only their prior would likely be too biased for general utility. Furthermore,
the role of a prior is buried too deeply in the computations of a posterior distribution to allow a
reader to assess the impact of a different prior on the types of Bayesian inference routinely provided.
Hence a standard of presentation is needed which will convey trial results for a wide spectrum of
assumed prior distributions.
The approach we take is to use a spectrum of normal prior distributions specified by their
mean and standard deviation. Such a choice has several advantages, as well as disadvantages. The
primary advantage is that a normal prior is specified entirely by two parameters, greatly reducing
the dimension of the space of prior distributions to be considered, while still covering a very broad
range of choices for the prior. Furthermore, means and standard deviations are commonly used and
understood by many researchers. The mean of the prior distribution will in some sense measure
the optimism or pessimism in the prior, and the standard deviation of the prior distribution can be
regarded as a measure of dogmatism in those prior beliefs, with lower standard deviations for the
prior indicative of more dogmatic beliefs about the benefit or lack of benefit (harm) of the treatment
a priori. Many researchers are also quite familiar with common properties of the “bell-shaped”
curve, such as the fact that approximately 95% of the measurements are within two standard
deviations of the mean.
This approach is probably the most obvious standard in a setting in which investigators have not
truly characterized their entire prior distribution, but do have ideas of a prior mean and standard
deviation for the treatment effect parameter. In this setting, using a normal prior will tend to
underestimate the amount of information in an individual’s true prior. The normal distribution
is known to maximize entropy over the class of all priors having the same first two moments.
This property suggests that in our approach we will in some sense use the least informative of
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all distributions that could reasonably reflect an individual’s true prior. This is beneficial to the
extent that many researchers tend to voice priors that are too dogmatic for the available prior
information or, indeed, their actions. This is potentially deleterious if an individual’s well-based
prior is more informative than the normal prior with the same mean and standard deviation. In the
latter case, a Bayesian analysis with a normal prior may suggest that the data has overwhelmed
an investigator’s initial belief, when it in fact has not. This latter problem can be ameliorated
somewhat by the investigator considering other normal priors that are either more informative
(i.e., priors having lower standard deviations), more extreme (i.e., priors having means that are
further from the observed value of θ̂), or both.
The choice of normal priors also offers a computational advantage when the distribution of the
treatment effect estimate does not exhibit a mean-variance relationship, i.e., when V (θ) is constant.
In this case, the normal distribution is the conjugate prior for the asymptotic distribution of θ̂|θ,
and the posterior distribution is then known to be normal as well. This computational advantage
is increasingly less important, however, with the advent of advanced computational methods such
as Markov chain, Monte Carlo.
Under the probability model θ̂N | θ ∼N
˙ (θ, V /N ) (so no mean-variance relationship) and a prior
distribution θ ∼ N (ζ, τ 2 ), the posterior distribution for the treatment effect is
θ | θ̂N ∼N
˙

1
(1/τ 2 )ζ + (N/V )θ̂N
,
(1/τ 2 ) + (N/V )
(1/τ 2 ) + (N/V )

!

.

It is often useful to measure the variance of the prior distribution as the “effective sample size” in
the prior information. That is, if N0 = V /τ 2 , the prior distribution is as informative as the posterior
distribution from a Bayesian analysis of a sample of N0 subjects and an initially noninformative
prior. Similarly, for a study having sample size N , the ratio V /(N τ 2 ) measures the statistical
information presumed in the prior relative to the statistical information contributed by the new
data.
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4

Evaluation of Stopping Rules

The Bayesian evaluation of stopping rules proceeds much the same as for the evaluation of stopping
rules with respect to frequentist inference. The major difference relates to the magnitude of the
results that need to be presented. When evaluating a stopping rule with respect to frequentist
inference, we present the estimate, confidence interval, and P value for clinical trial results corresponding to the stopping boundaries. For Bayesian inference, we must consider how that inference
is affected by the choice of prior.
We illustrate Bayesian evaluation of a stopping rule in the context of the sepsis clinical trial
example. For ease of presentation, in the example presented here, we suppress the mean-variance
relationship inherent in the binomial probability model. Hence, in evaluating the design, we use a
variance V = 0.7742, which corresponds to the average variance contributed by each observation
under the design alternative of 30% 28 day mortality on the control arm and 23% 28 day mortality
on the antibody arm.
We specify a pessimistic prior in order to judge whether trial results corresponding to a decision
for efficacy (i.e., below the lower stopping boundary) are so strong as to convince a person who
believed the new treatment was not efficacious, or even was harmful. Similarly we specify an
optimistic prior in order to judge the strength of evidence when trial results correspond to a
decision that the new treatment is not sufficiently efficacious to warrant further study. We also
consider a prior representing the consensus of opinion of trial collaborators and consultants to the
trial sponsor.
A pessimistic prior for this trial might be centered at a prior mean of ζ = 0.02, suggesting that
treatment with the antibody provides harm to the population of treated patients. An optimistic
prior, on the other hand, might be centered on a prior mean of ζ = −0.09, representing a treatment
effect greater than the 7% absolute improvement in 28 day mortality used in the sample size
computation. The strength of optimism or pessimism in the prior is also affected by the standard
deviation of the prior distribution for the treatment effect. For instance, a choice of τ = 0.015
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is relatively dogmatic, because it suggests that accrual of the full sample size of 1700 subjects
provides only half the amount of information about the treatment effect as is already included in
the prior. As τ becomes very large, the prior is increasingly less informative about the magnitude
of the treatment effect.
When this phase III sepsis study was conducted, preliminary data was available from several
phase II and phase III studies which showed some promising trends toward benefit, especially
in some important subgroups. Given this preliminary data, it would seem quite reasonable to
base a prior for θ on the analysis results from those previous studies. Several factors mitigate
against doing this blindly, however. First, although it was scientifically plausible that greater
treatment effect might be seen in the subgroups identified in the earlier studies, identification of
the subgroups of greatest interest was in fact based on some post hoc data-driven analyses. Because
Bayesian analyses are no more able than frequentist analyses to handle the multiple comparison
issues inherent in such data dredging, it is wise to discount the results from the earlier studies in
anticipation of some “regression to the mean”. Also, the inclusion/exclusion criteria were modified
for the planned study, so it would be inappropriate to assume that the statistical information in the
prior should reflect the full sample size previously exposed to the antibody. A reasonable subjective
prior based on the preliminary studies might then consider a prior mean for θ of ζ = −0.04, and the
statistical information presumed in the prior might correspond to the prior distribution having a
standard deviation of τ = 0.04, which suggests that the information in the data from 1700 subjects
is approximately 3.5 times the information that is presumed in the prior.
The general idea is then to present the inference which would be made if the study were to stop
with specific results. Table 1 presents the posterior probability of a beneficial treatment (i.e., the
posterior probability that θ < 0) for trial results corresponding exactly to the efficacy boundary
and, for trial results corresponding to the futility boundary, the posterior probability that the
treatment is not sufficiently beneficial to warrant further study (i.e., the posterior probability that
θ > −0.087, which is the alternative for which the planned study has power 0.975). The priors
considered in Table 1 include the optimistic, sponsor’s consensus, and pessimistic priors centered
at ζ = −0.09, -0.04, and 0.02, respectively, with standard deviations corresponding to a high level
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Table 1:

Posterior probabilities of hypotheses for trial results corresponding to stopping boundaries of F utility.8 stopping rule
with four equally spaced analyses after 425, 850, 1275, and 1700 subjects have been accrued to the study. Posterior probabilities
are computed based on optimistic, the sponsor’s consensus, and pessimistic centering of the priors using three levels of assumed
information in the prior. The variability of the likelihood of the data corresponds to the alternative hypothesis: event rates of
0.30 in the control group and 0.23 in the treatment group.
Efficacy (lower) Boundary

Futility (upper) Boundary

Posterior Probability of
Beneficial Treatment Effect
Pr(θ < 0|X)

Posterior Probability of
Insufficient Benefit
Pr(θ ≥ −0.087|X)

Analysis
Time

Crude Est
of Trt
Effect

Optimistic
ζ = −.09

1:N=425
2:N=850
3:N=1275
4:N=1700

-0.170
-0.085
-0.057
-0.042

1.000
1.000
1.000
1.000

1:N= 425
2:N= 850
3:N=1275
4:N=1700

-0.170
-0.085
-0.057
-0.042

1:N= 425
2:N= 850
3:N=1275
4:N=1700

-0.170
-0.085
-0.057
-0.042

Sponsor’s
Consensus
ζ = −.04

Optimistic
ζ = −.09

Sponsor’s
Consensus
ζ = −.04

Pessimistic
ζ = .02

Dogmatic Prior: τ = 0.015
1.000
0.524
0.047
1.000
0.523
-0.010
1.000
0.522
-0.031
1.000
0.521
-0.042

0.795
0.824
0.836
0.842

1.000
1.000
1.000
1.000

1.000
1.000
1.000
1.000

1.000
1.000
0.999
0.998

Consensus Prior: τ = 0.040
1.000
0.991
0.047
0.998
0.974
-0.010
0.993
0.955
-0.031
0.987
0.936
-0.042

0.981
0.976
0.970
0.963

0.999
0.997
0.994
0.991

1.000
1.000
1.000
0.999

1.000
0.998
0.989
0.977

Noninformative Prior: τ = ∞
1.000
1.000
0.047
0.998
0.998
-0.010
0.989
0.989
-0.031
0.977
0.977
-0.042

0.999
0.995
0.988
0.981

0.999
0.995
0.988
0.981

0.999
0.995
0.988
0.981

Pessimistic
ζ = .02

Crude Est
of Trt
Effect

of dogmatism, the sponsor’s consensus, and noninformative τ = 0.015, 0.04, and ∞, respectively.
This table illustrates the impact that choice of prior can have on Bayesian inference.
For instance, the Futility.8 design ultimately selected as the stopping rule for the clinical trial
would suggest that the trial would be stopped for efficacy (i.e., the trial results suggest a true
benefit due to treatment with antibody) if the estimate of treatment effect were θ̂ = −0.0866 after
850 subjects (425 per arm) had been accrued to the study. With a dogmatic prior centered on a
pessimist’s belief that the treatment was truly harmful, the posterior probability of a true benefit
due to treatment is only 0.523 after obtaining such results. Equally dogmatic priors centered at the
sponsor’s consensus prior belief or an optimist’s prior belief of treatment effect suggest near certain
posterior probabilities of treatment benefit. As less dogmatic priors corresponding to the level
of information in the sponsor’s consensus prior are used, those posterior probabilities are 0.974,
0.998, and 1.000. When noninformative (flat) priors are used as the basis for Bayesian inference,
identical values are obtained for the pessimistic, sponsor’s consensus, and optimistic centering of
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the priors: a posterior probability of a beneficial treatment of 0.998. This latter result is exactly
1 minus the fixed sample P value for this trial outcome (see Table 1 in the companion paper on
frequentist evaluation [1])– a correspondence that is obtained whenever a flat prior is used for
Bayesian inference.
The difference between the conservatism of the efficacy and futility boundaries for this trial is
evident in the Bayesian posterior probabilities corresponding to stopping at each analysis. The
Futility.8 design would suggest that the trial would be stopped for futility (i.e., the trial results
do not suggest sufficient benefit from the treatment to warrant further study of the antibody in
this clinical trial) if the estimate of treatment effect were θ̂ = −0.0097 after 850 subjects (425 per
arm) had been accrued to the study. Under the sponsor’s consensus prior, the posterior probability
~ ) = 0.997 is slightly less certain than that when stopping for efficacy.
P r(θ > −.0866|X
Although such a prior fairly accurately reflects the prior beliefs elicited from the study sponsors
during the selection of the stopping rule, as noted above, it is important to also report the result of
Bayesian analyses for a spectrum of priors. For instance, one logical strategy would be to evaluate
the futility boundary under an optimistic prior, because the burden of proof for establishing futility
should be to convince the optimists. Similarly, the efficacy boundary might be evaluated under
a pessimistic prior. It is interesting to note from Table 1 that the futility boundary is somewhat
paradoxically anti-conservative from the viewpoint of a researcher with the optimistic, dogmatic
prior: Stopping for futility at the first analysis confers less certainty about an insufficiently effective
treatment than does the stopping boundary at later analyses.
The optimistic and pessimistic priors presented in Table 1 were chosen rather arbitrarily, and
thus may not be relevant to some of the intended audience for the published results of a clinical
trial. We thus can also present contour plots of Bayesian point estimates (posterior means), lower
and upper bounds of 95% credible intervals, and posterior probabilities of the null and alternative
hypotheses for a spectrum of prior distributions.
The mean and standard deviation of the prior distribution is probably the most scientifically
relevant, while being statistically concise, way to specify the normal prior, as both the mean and
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standard deviation are in the units of the treatment effect parameter itself. For this reason, when
displaying Bayesian inferential statistics as a function of the prior in a contour plot, we label the
x-axis by the mean of the normal prior and the y-axis by the prior standard deviation. However,
there are additional scales on which it is at times useful to characterize the prior distribution. In the
case of the prior mean for the treatment effect parameter θ, it is often useful to consider the power
of the designed clinical trial to detect a particular value of θ. This is particularly the case when
the stopping rule corresponds to a frequentist trial design in which the study has been adequately
powered to detect the minimal treatment effect judged to be of clinical importance. We thus find
it useful at the top of the contour plot to provide readers with an alternative labeling of the x-axis
according to the power of a frequentist test based on the stopping rule.
Similarly, at the right side of the contour plot, we provide readers with an alternative scale for
the standard deviation of the prior distribution. When using a conjugate normal prior distribution
with a normal sampling distribution for the estimated treatment effect, the mean of the posterior
distribution for θ|θ̂ is a weighted average of the prior mean and θ̂, where the weights are the
statistical information in the prior (equal to 1/τ 2 , where τ is the standard deviation of the prior
distribution) and the statistical information in the approximate likelihood for θ̂ (equal to N/V (θ)).
It may therefore be of interest to consider the ratio of information presumed in the prior to the total
information expected if the study were to continue until the maximal sample size were accrued. On
the right axis of the contour plot we display for selected values of τ the value of NJ /(V (θ)τ 2 ). As
that ratio goes to 0 (equivalently, as τ becomes large), the prior is tending to be “noninformative” in
that all information in the posterior distribution is derived from the data rather than from the prior.
Bayesian inference with noninformative priors result in similar point estimates, confidence intervals,
and statistical decisions as derived under frequentist procedures, though the interpretation of those
inferential measures remains different.
As a general rule, we might expect that priors which contain more information than would
be present in the maximal sample size for the study would not be very reasonable for the study
investigators as a whole (Why would they bother doing the study if the complete data were unable
to sway their opinion?). Nonetheless, other members of the scientific community may indeed have
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such dogmatic priors.
Lacking any other particular criteria by which to choose the range of means ζ and standard
deviations τ for the prior distribution which should be considered, we choose values of prior mean ζ
corresponding to the values of θ for which the frequentist test based on the stopping rule would have
power between 0.001 and 0.999, and we choose values of the standard deviation τ corresponding
to prior information ranging between one-twentieth to four times as much information as would be
present in the data should the study continue until 1700 subjects were accrued. Figure 1 presents
contours of the Bayesian point estimate of treatment effect which would be reported under the
spectrum of priors described above. From the plot we see that use of the sponsor’s consensus prior
of θ ∼ N (ζ = −0.04, τ 2 = .042 ) would suggest that upon observing a difference in proportions
of -0.0097, the mean, median, and mode of the posterior distribution is -0.021. Note that an
individual who before the study was quite sure the treatment worked and thus had a prior of
θ ∼ N (ζ = −0.08, τ 2 = .0152 ) would use the posterior mean of -0.067 as the point estimate of
treatment effect. Of course, such an individual was assuming a prior that was twice as informative
as would be provided by data on 1700 subjects, as indicated by the dotted horizontal line.
Similar contour plots can be constructed for the lower and upper bounds for the 95% credible
interval, as well as the posterior probability of the null and design alternative hypotheses. At the end
of a clinical trial, contour plots such as these can be used in a report of Bayesian inference, thereby
allowing readers to assess the credibility of the results across a wide range of priors. At the design
phase, when we are trying to assess the Bayesian operating characteristics of the entire stopping rule,
such plots can be shown for results which correspond to each of the stopping boundaries. Figure
2 shows such a plot for a stopping rule with boundaries the same shape as those for Futility.8,
but having only two analyses: one interim analysis halfway through the study (i.e., after 425
patients accrued to each arm) and the final analysis when 1700 subjects (850 per arm) have been
accrued. The contours in each panel are the posterior probability that the decision made by the
frequentist stopping rule is correct. Thus for the futility (upper) boundary which rejects (with
97.5% confidence) the design alternative H1 : θ < − 0.085, we display the posterior probability
P r(θ > −0.085|(M, θ̂NM )) for each of the futility (upper) boundaries, where M is the analysis
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Prior Information About θ as Proportion of
Information From Maximal Sample Size
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0.0
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Prior Median for θ

Figure 1: Contours of posterior mean (median) conditional on observing an estimated treatment
effect of -0.0097 after accruing 850 subjects (425 per arm). Contours are displayed for normal prior
distributions as a function of the mean (median) and standard deviation of the prior distribution,
with the prior corresponding to the sponsor’s consensus prior indicated by an X. Top axis displays
the power of the hypothesis test corresponding to stopping rule F utility.8, and the right hand axis
displays the prior information in the prior as a proportion of the statistical information in a sample
size of 1700 subjects (850 per arm).

index and θ̂NM is the difference in proportions which corresponds to the futility boundary at that
analysis. Similarly, for the efficacy (lower) boundary which rejects (with 97.5% confidence) the null
hypothesis H0 : θ ≥ 0, we display P r(θ < 0|(M, θ̂NM )) for each of the efficacy (lower) boundaries.
The leftmost panel in each row are the contours for the corresponding prior probability of each
hypothesis.
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Figure 2: Contours of posterior probabilities at the boundaries for a stopping rule having a maximum of 2 analyses and boundary shapes similar to the F utility.8 stopping rule. The upper row
relates to decisions for futility: to reject the alternative hypothesis that θ < −0.0849 (the alternative
for which the design has 97.5% power) or, equivalently, to accept the hypothesis that the treatment
is not sufficiently beneficial (θ > −0.0849). The lower row relates to decisions for efficacy: to reject
the null hypothesis that θ ≥ 0 or, equivalently, to accept the hypothesis that the treatment has
some beneficial effect (θ < 0). In each row, the leftmost column considers the prior probability that
the decision to reject the corresponding hypothesis will be correct, the middle column considers
the posterior probability that the decision reached at the first interim analysis (with 850 subjects
accrued, 425 per arm) will be correct, and the rightmost considers the posterior probability of
a correct decision at the final analysis (with 1700 subjects accrued, 850 per arm). Contours are
displayed for normal prior distributions as a function of the mean (median) and standard deviation
of the prior distribution, with the prior corresponding to the sponsor’s consensus prior indicated
by an X. Top axis displays the power of the hypothesis test corresponding to the stopping rule,
and the right hand axis displays the prior information in the prior as a proportion of the statistical
information in a sample size of 1700 subjects (850 per arm).

From Figure 2, we see that the sponsor’s consensus prior corresponded to a P (θ > −0.085)
slightly less than 0.9. Stopping for futility at the interim analysis corresponds to a posterior
probability that θ > −0.085 between 0.99 and 0.999. It can also be seen that for all but the
most dogmatic of prior beliefs that the treatment had a marked benefit, stopping for futility at
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the interim analysis corresponds to a posterior probability greater than 0.9 that the treatment
does not provide as much as a 0.085 improvement in 28 day mortality. Similar evaluation of the
efficacy boundary can be made by considering the lower row of contour plots, where the greater
conservatism of the O’Brien-Fleming boundary relationship at the interim analysis leads to higher
posterior probabilities than are present for the futility boundary corresponding to a boundary shape
parameter of P = 0.8 (compare, for instance, the contours for posterior probabilities of 0.99 across
the two boundaries).
It is also possible to consider Bayesian prior distributions when evaluating stopping probabilities
and sample size distributions. Figure 3 displays the contours of the predicted sample size for the
Futility.8 boundary for a spectrum of prior distributions. For this plot however, we find it useful
to use truncated normal prior distributions. As the standard deviation of a normal prior increases,
increasing prior probability is placed on very extreme values of θ. In a stopping rule with two
boundaries, as the treatment effect θ gets very large or very small, the trial will tend to stop
at the first analysis with probability approaching 1. Thus noninformative priors will all tend to
suggest that the predicted sample size is that which corresponds to the timing of the first analysis.
To downplay such effects, for contour plots of the expected sample size we truncate the normal
distribution at specified values of θ, and renorm the prior so that it integrates to 1. For Figure 3
we arbitratily truncated the prior distribution at the values of θ for which the Futility.8 stopping
rule had power of 0.001 and 0.999. From this figure we see that under such a truncation of the
sponsor’s consensus prior the average sample size accrued to the study is between 1150 and 1200.
We note that as the standard deviation of the prior approaches 0, the lower limits of the contour
plot should correspond to the ASN curve for the stopping rule as shown in Figure 5b.
We can also use Bayesian methods to address the issue of economically important estimates
of treatment effect. When obtaining such an attractive estimate is of major importance, Bayesian
predictive probabilities may also be of use in judging whether it is useful to continue a clinical trial
in the hopes of obtaining an economically attractive estimate of treatment effect.
The Bayesian predictive probability is the probability that the estimate would exceed some
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Figure 3: Contours of expected sample sizes for the F utility.8 stopping rule based on truncated
normal priors. Contours are displayed for truncated normal prior distributions as a function of the
mean (median) and standard deviation of the normal distribution, with truncation at the values
corresponding to the 0.001 and 0.999 power points for the stopping rule. The prior corresponding
to the sponsor’s consensus prior is indicated by an X. Top axis displays the power of the hypothesis
test corresponding to the stopping rule, and the right hand axis displays the prior information in
the untruncated prior as a proportion of the statistical information in a sample size of 1700 subjects
(850 per arm).

specified threshold at a particular analysis. The computation uses the updated distribution of
the treatment effect parameter at the j-th analysis (i.e., the posterior distribution conditioned
on the observed data at the j-th analysis) along with the sampling distribution of the as yet
unobserved data. Using the coarsened approach based on the approximate normal distribution for
the estimated difference in 28 day mortality rates and the computationally convenient conjugate
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normal prior θ ∼ N (ζ, τ 2 ), at the jth analysis we can define an approximate Bayesian posterior
distribution for the true treatment effect θ conditioned on the observation θ̂j as

θ|θ̂j ∼N
˙

θ̂j τ 2 + ζσ 2 /Nj τ 2 σ 2 /Nj
,
τ 2 + σ 2 /Nj τ 2 + σ 2 /Nj

!

.

Then, using the sampling distribution for the as yet unobserved data and integrating over the
posterior distribution, the predictive distribution for the estimate θ̂J at the final analysis is

θ̂J |θ̂j ∼N
˙

(τ 2 + σ 2 /NJ )Πj θ̂j + (1 − Πj )ζσ 2 /NJ (1 − ΠJ )(τ 2 + σ 2 /NJ )σ 2 /NJ
,
Πj τ 2 + σ 2 /NJ
Π2j (ΠJ τ 2 + σ 2 /NJ )

!

.

We might therefore compute a predictive probability of an economically attractive treatment estimate less than some threshold c as
Z

P r(θ̂J < c | Sj = sj , θ) p(θ | Sj = sj ) dθ = Φ

[Πj τ 2 + σ 2 /NJ ][c − θ̂j ] + [1 − Πj ][θ̂j − ζ]σ 2 /NJ
p
[1 − Πj ][τ 2 + σ 2 /NJ ][Πj τ 2 + σ 2 /Nj ]σ 2 /NJ

!

.

The case of a noninformative (although improper) prior is of special interest. When we consider
taking the limit as τ 2 → ∞), the predictive probability becomes
Z

P r(θ̂J < c | Sj = sj , θ) p(θ | Sj = sj ) dθ = Φ

!
p
(c − θ̂j ) Πj
p
.
[1 − Πj ]σ 2 /NJ

For instance, for a result corresponding to a crude estimate of treatment effect of -0.0566 at
the third analysis, the predictive probability of obtaining a crude estimate of treatment effect less
than -0.06 at the final analysis is 35.0% under the sponsor’s consensus prior and 39.0% under
a noninformative prior. In either case, such high probabilities of obtaining a more economically
viable estimate of treatment effect may be enough to warrant modifying the stopping rule to avoid
early termination at the third analysis with a crude estimate between -0.0566 and -0.06. On the
other hand, had the minimal economically viable estimate been -0.08, the predictive probabilities
of obtaining such an estimate at the fourth analysis after observing -0.0566 at the third analysis are
1.92% and 2.86% under the sponsor’s consensus and noninformative priors, respectively, and such
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low probabilities would likely be regarded as support for a clinical trial design based on a smaller
maximal sample size.

5

Summary

In this manuscript we have described a general approach to the evaluation of a stopping rule
with respect to its Bayesian operating characteristics. Such evaluation is complementary to the
exploration of frequentist operating characteristics described in our companion paper [1]. Using
a prior distribution for the parameter measuring treatment effect, the Bayesian evaluation of the
clinical trial design might typically include the following analogues to the frequentist evaluation
criteria:

1. The sample size distribution averaged across a Bayesian prior distribution for the true treatment effect.
2. The Bayesian predictive probability that the trial would continue to each analysis.
3. The Bayesian inference (posterior mean or mode, credible intervals, and posterior probabilities
of hypotheses) which would be reported were the trial to stop with results corresponding
exactly to a boundary.
4. The Bayesian predictive probability of obtaining a point estimate which exceeds some economically relevant threshold.

Each of the above criteria will, of course, vary according to the prior distribution assumed for
the parameter measuring treatment effect. Because different people will have different priors, it is
important that an attempt be made to communicate how the Bayesian operating characteristics
will vary as a function of the prior distribution. In this paper, we have suggested that a contour
plot would be presented for each of the most important measures. This will not, however, always
be feasible for every Bayesian analysis, and thus standards will also have to be adopted for a more
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parsimonious presentation of Bayesian analyses. Numerical results based on a single consensus prior
may be acceptable when there is widespread agreement on the prior. Other times the strength of
evidence may be sufficiently strong that one can simply document the most pessimistic prior still
consistent with decisions for treatment benefit or the most optimistic prior still consistent with
decisions for lack of benefit. In any case, the general “coarsened Bayesian” approach would argue
that a sufficient statistic for a reader to apply his or her own prior would be the estimate θ̂ and the
standard error estimate, when that estimator is approximately normally distributed. We note that
such an estimator will not in general correspond to the least biased frequentist estimate. Thus, it
will generally be the case that the clinical trial results should report both the unadjusted estimator
and an estimator adjusted for the stopping rule.
In this paper and its companion paper, we have made the case for frequentist and Bayesian
evaluation of clinical trials. We have not addressed other methods such as those based purely on
the Likelihood principle. Though quantification of statistical evidence via the Likelihood principle
has received much attention [12, 13, 14], we have chosen not to consider these methods in our
evaluation of clinical trials. The absence of a discussion on this topic stems from the fact that
the definition of statistical evidence via the ratio of likelihoods does not provide any probabilistic
interpretation regarding the effect of an experimental treatment. Likelihood ratio values of 8 and
32 have been proposed for distinguishing between weak, moderate and strong evidence in favor
of one hypothesis over another [13], yet without a probabilistic interpretation of the value of the
likelihood ratio the relevance of these cutoffs is questionable in our minds. Similar problems exist
with the construction of support intervals for parameter estimation via the Likelihood principle.
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